Pharma BD Deal Intelligence
AstraZeneca's $39B acquisition of Alexion brought the rare disease leader's complement franchise—Soliris and Ultomiris—into a top-5 pharma company. The deal gave AZ a $6B+ rare disease revenue base and diversification beyond oncology, though the premium remained controversial.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
AstraZeneca and Alexion today announced that they have entered into a definitive agreement under which AstraZeneca will acquire Alexion for $175 per share,…
AstraZeneca has entered into a definitive agreement to acquire Alexion Pharmaceuticals, a leader in rare diseases and complement biology, for approximately…
AstraZeneca FY2024 results (6 Feb 2025): Total Revenue from Rare Disease medicines $7,764m, 16-17% of overall Total Revenue; Ultomiris FY2024 revenue…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
AstraZeneca acquired Alexion Pharmaceuticals for approximately $39 billion, establishing a new rare disease franchise anchored by complement inhibitors Soliris and Ultomiris, accelerating AstraZeneca's strategic and financial development toward its $40 billion revenue target.
70K US cases/yr · $3.0B Global gMG Market (2024)
Generalized myasthenia gravis is an autoimmune neuromuscular disorder. The treatment paradigm has been transformed by complement inhibitors (Ultomiris/Soliris) and FcRn inhibitors (Vyvgart), expanding the market from traditional immunosuppression to targeted therapy.
argenx (Vyvgart, $2B+) leads the FcRn class. AZ/Alexion (Ultomiris) competes on the complement side. UCB (Rystiggo), J&J (nipocalimab), and Immunovant are expanding options.
22K US cases/yr · $650M Global NMOSD Market (2024)
NMOSD is a rare autoimmune disorder of the CNS. Anti-AQP4 antibodies drive disease in 70-80% of patients. Complement inhibition, IL-6 blockade, and CD19 depletion have established a new treatment era.
AZ/Alexion Soliris/Ultomiris (eculizumab/ravulizumab, terminal complement C5 inhibitors) are approved for anti-AQP4-positive NMOSD. Roche/Chugai Enspryng (satralizumab, anti-IL-6 receptor monoclonal antibody) is a subcutaneous q4-week option. Amgen/Horizon Uplizna (inebilizumab, anti-CD19 B-cell depleting monoclonal antibody) is an IV option. All three drug classes significantly reduce relapse risk in AQP4-IgG seropositive disease.
10K US cases/yr · $6.0B Global PNH Market (2024)
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematopoietic stem-cell disorder caused by somatic PIGA mutations that impair GPI-anchored complement regulators (CD55, CD59) on blood cells. This leads to complement-mediated intravascular hemolysis, thrombosis (the leading cause of death), and bone marrow failure. Estimated prevalence is ~1-5 per million. Terminal-complement C5 inhibition (eculizumab, ravulizumab) transformed survival; proximal complement inhibition (C3, Factor B, Factor D) addresses residual extravascular hemolysis.
AZ/Alexion dominates with Soliris/Ultomiris ($7B+ combined). Apellis (Empaveli, C3 inhibitor) and Novartis (Fabhalta, oral Factor B) are expanding the market. The shift to oral therapies and proximal complement targets is the key competitive dynamic.
8K US cases/yr · $6.5B Global PNH Market (2024)
PNH is a rare, life-threatening blood disease caused by complement-mediated destruction of red blood cells. Alexion pioneered complement inhibition with Soliris (eculizumab) and next-generation Ultomiris (ravulizumab), creating a ~$9B rare disease franchise now under AstraZeneca.
AstraZeneca Rare Disease division manages Soliris, Ultomiris, Strensiq, and Kanuma. Pipeline expansion includes gefurulimab (Phase 3 success in MG), gene therapy programs via LogicBio and Pfizer deals. Complement biology platform extends beyond PNH to aHUS, MG, and NMOSD.
4K US cases/yr · $1.4B Global aHUS Market (2024)
aHUS is a rare complement-mediated thrombotic microangiopathy. Complement inhibitors transformed outcomes from >50% mortality to manageable chronic condition.
AZ/Alexion (Ultomiris) dominates. Novartis (Fabhalta) is investigating oral Factor B inhibition for aHUS.
AstraZeneca announces agreement to acquire Alexion Pharmaceuticals for $39B at $175/share, adding rare disease as a new therapeutic pillar alongside oncology and respiratory.
US Federal Trade Commission authorizes the AstraZeneca-Alexion acquisition without conditions, the first of several required regulatory approvals.
AstraZeneca and Alexion shareholders both vote to approve the acquisition, clearing the corporate governance hurdle for the transformative rare disease deal.
UK Competition and Markets Authority clears the acquisition as the final regulatory approval, enabling close within two weeks.
AstraZeneca completes acquisition of Alexion for $39B ($60 cash + 2.1243 ADS per share), establishing 'Alexion, AstraZeneca Rare Disease' unit headquartered in Boston.
Alexion's complement franchise generates nearly $6B in combined Soliris/Ultomiris sales in 2022, validating the rare disease acquisition thesis for AstraZeneca.
AstraZeneca reports $54B in 2024 total revenue (21% YoY growth). Ultomiris conversion from Soliris progresses well with rare disease unit contributing significantly to growth.
Alexion acquisition validated as growth engine. Rare disease unit adds ~$7B+ annually, Ultomiris transition on track, AZ revenue nearly doubled from $26B (2020) to $54B (2024). Clear strategic win.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. (this deal) | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2020 deals · AstraZeneca PLC deals · Hematology deals